1
|
Kast K, Rhiem K, Larsen M, Wappenschmidt B, Schmutzler R. Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne. Cancer Med 2024; 13:e6920. [PMID: 38230850 PMCID: PMC10905677 DOI: 10.1002/cam4.6920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 12/07/2023] [Accepted: 12/31/2023] [Indexed: 01/18/2024] Open
Abstract
PURPOSE Tumor protein p53 (TP53) pathogenic variant (PV) carriers are identified during genetic testing for hereditary causes of cancer. PVs in TP53 are associated with the Li-Fraumeni syndrome (LFS), and thus, surveillance and preventive measures are important for TP53 PV carriers. However, the penetrance of TP53 PVs can be low if the Chompret criteria are not fulfilled. In this study, we compared the phenotypic characteristics of families that did and did not fulfill the LFS criteria according to Chompret. METHODS The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) database was used to identify index patients with a likely pathogenic/pathogenic TP53 variant and their family members. The study investigated the type of variant, pedigree, age of onset, number of primary tumors, and histological type of BC. RESULTS TP53 PV were present in the index cases of 35 families, 57% (20/35) of which fulfilled the Chompret criteria. The median age of onset at first BC diagnosis was lower in families that fulfilled the Chompret criteria compared to those who did not. Four of all diseased individuals were minors (4%; 4/105) when malignancy was first diagnosed. Sarcomas and brain tumors occurred in 10% (10/105) and in 7% (7/105) of all diseased persons, respectively. BC was the most frequently occurring first tumor (60%; 62/105) and additional malignancy (45%; 20/44) in this cohort. Subsequent malignancies developed in 31% (20/65) of the individuals who fulfilled the Chompret criteria compared with 15% (6/40) of those who did not. CONCLUSION The tumor spectrum and age of onset found in this study showed that tumors other than BC had low disease penetrance in TP53 PV carriers identified using the GC-HBOC criteria for genetic testing.
Collapse
Affiliation(s)
- K. Kast
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| | - K. Rhiem
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| | - M. Larsen
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| | - B. Wappenschmidt
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| | - R. Schmutzler
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| |
Collapse
|
2
|
Geyer C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong A, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek S, Eisen A, Elsafy F, Fein L, Fielding A, Ford J, Friedman S, Gelmon K, Gianni L, Gnant M, Hollingsworth S, Im SA, Jager A, Jóhannsson Ó, Lakhani S, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas P, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer C, Španić T, Stickeler E, Toi M, Traina T, Viale G, Zoppoli G, Park Y, Yerushalmi R, Yang H, Pang D, Jung K, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke G, Sun Q, Parton M, Colleoni M, Schmidt M, Brufsky A, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt A. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. Ann Oncol 2022; 33:1250-1268. [PMID: 36228963 DOI: 10.1016/j.annonc.2022.09.159] [Citation(s) in RCA: 115] [Impact Index Per Article: 57.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 09/22/2022] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. PATIENTS AND METHODS One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. RESULTS With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI -0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. CONCLUSION With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals.
Collapse
|
3
|
Isselhard A, Töpper M, Steckelberg A, Berger-Höger B, Vitinius F, Köberlein-Neu J, Manderscheid L, Wiedemann R, Rhiem K, Schmutzler R, Stock S. Workshop: Corona Pandemie – Herausforderungen nicht nur für die Grundlagenwissenschaften. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- A Isselhard
- Institut für Gesundheitsökonomie und klinische Epidemiologie, Universitätsklinikum Köln
| | - M Töpper
- Institut für Gesundheitsökonomie und klinische Epidemiologie, Universitätsklinikum Köln
| | - A Steckelberg
- Instituts für Gesundheits- und Pflegewissenschaft, Martin-Luther-Universität Halle-Wittenberg
| | - B Berger-Höger
- Instituts für Gesundheits- und Pflegewissenschaft, Martin-Luther-Universität Halle-Wittenberg
| | - F Vitinius
- Klinik und Poliklinik für Psychosomatik und Psychotherapie, Universitätsklinikum Köln
| | - J Köberlein-Neu
- Bergisches Kompetenzzentrum für Gesundheitsökonomik und Versorgungsforschung, Bergische Universität Wuppertal
| | - L Manderscheid
- Bergisches Kompetenzzentrum für Gesundheitsökonomik und Versorgungsforschung, Bergische Universität Wuppertal
| | - R Wiedemann
- Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln
| | - K Rhiem
- Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln
| | - R Schmutzler
- Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln
| | - S Stock
- Institut für Gesundheitsökonomie und klinische Epidemiologie, Universitätsklinikum Köln
| |
Collapse
|
4
|
Tripon D, Harter P, Rhiem K, Schneider S, du Bois A, Heitz F, Baert T, Traut A, Pauly N, Ehmann S, Schmutzler R, Ataseven B. Prävalenz von BRCA1 and BRCA2 Mutationen bei Patientinnen mit primärem Ovarialkarzinom – Bildet die deutsche Checkliste zur Erfassung des Risikos für familiären Brust-/und Eierstockkrebs den Beratungsbedarf ausreichend ab? Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- D Tripon
- Kliniken Essen-Mitte
- LMU Klinik für Frauenheilkunde und Geburtshilfe
| | | | - K Rhiem
- Zentrum Familiärer Brust- und Eierstockkrebs
| | | | | | - F Heitz
- Kliniken Essen-Mitte
- Charite Berlin, Gynäkologie
| | - T Baert
- Kliniken Essen-Mitte
- Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group
| | | | | | | | | | - B Ataseven
- Kliniken Essen-Mitte
- LMU Klinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
5
|
Herold N, Bredow K, Hahnen E, Wappenschmidt B, Hauke J, Wiedemann R, Waha A, Blümcke B, Portnicki M, Pohl-Rescigno E, Rhiem K, Kast K, Hübbel V, Maringa M, Crombach G, Schmutzler R. Wissen-generierende Versorgung am Beispiel des erblich bedingten Mamma- und Ovarialkarzinoms (BC/OC): Evaluation des flächendeckenden Versorgungskonzepts. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- N Herold
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - K Bredow
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - E Hahnen
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - B Wappenschmidt
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - J Hauke
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - R Wiedemann
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - A Waha
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - B Blümcke
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - M Portnicki
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - E Pohl-Rescigno
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - K Rhiem
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - K Kast
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - V Hübbel
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - M Maringa
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - G Crombach
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - R Schmutzler
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| |
Collapse
|
6
|
Puppe J, Liu X, Ratz L, Bartke L, van de Ven M, Vliet MH, Wientjes E, van der Gulden H, Zevenhoven J, Hahnen E, Malter W, Wessels LFA, Schmutzler R, Mallmann P, Reinhardt C, Linn S, Jonkers J. Double BRCA1 and BRCA2 inactivation is epistatic in mammary tumorigenesis and treatment response to PARP-inhibition and platinum drugs. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- J Puppe
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | - X Liu
- Netherlands Cancer Institute
| | - L Ratz
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | - L Bartke
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | | | | | | | | | | | - E Hahnen
- Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln
| | - W Malter
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | | | - R Schmutzler
- Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln
| | - P Mallmann
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | | | - S Linn
- Netherlands Cancer Institute
| | | |
Collapse
|
7
|
Puppe J, Brambillasca C, Ratz L, Bartke L, van de Ven M, Bouwman P, van Tellingen O, Isensee J, Hucho T, van Lohuizen M, Malter W, Schmutzler R, Mallmann P, Jonkers J, Reinhardt C. Dual inhibition of EZH2 and ATM displays synergistic cytotoxicity in BRCA1-deficient breast cancers. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- J Puppe
- Uniklinik Köln, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | | | - L Ratz
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | - L Bartke
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | | | | | | | | | | | | | - W Malter
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | - R Schmutzler
- Zentrum Familiärer Brust- und Eierstockkrebs, Uniklinik Köln
| | - P Mallmann
- Klinik und Poliklinik für Frauenheilkunde, Uniklinik Köln
| | | | | |
Collapse
|
8
|
Isselhard A, Töpper M, Berger-Höger B, Steckelberg A, Fischer H, Vitinius F, Beifus K, Köberlein-Neu J, Wiedemann R, Rhiem K, Schmutzler R, Stock S. Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study. Trials 2020; 21:501. [PMID: 32513307 PMCID: PMC7278068 DOI: 10.1186/s13063-020-04431-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 05/19/2020] [Indexed: 12/16/2022] Open
Abstract
Background Female BRCA mutation carriers have an increased lifetime risk for breast and ovarian cancer compared to the general population. Women who carry this mutation have several options to deal with their cancer risk, such as risk-reducing surgeries or intensified breast cancer screening. Previous research has shown that preferences in this scenario are highly dependent on affected women’s personalities and value systems. To support these women in the decision-making process, a structured decision support consisting of decision coaching combined with a decision aid might be helpful. Methods/design A randomized controlled trial will be conducted in order to compare usual care with structured decision support alongside usual care. The decision support program entails nurse-led decision coaching as well as an evidence-based patient decision aid. Nurses are qualified by a 4-day training program in informed decision-making and decision coaching. Six centers for Familial Breast and Ovarian Cancer in Germany will be included in the study, with a planned sample size of 398 women. The primary outcome is the congruence between the preferred and the actual played role in the decision-making process as measured by the Control Preferences Scale. It is hypothesized that the structured decision support will enable women to play the preferred role in the decision-making process. Secondary outcomes include the knowledge and attitudes about preventive options, decisional conflict, depression and anxiety, coping self-efficacy, impact of event, and self-concept. A process evaluation will accompany the study. Discussion The EDCP-BRCA study is the first study to implement and evaluate decision coaching combined with a decision aid for healthy BRCA mutation carriers worldwide. Trial registration {2a} DRKS-ID: DRKS00015527. Registered 30 October 2019.
Collapse
Affiliation(s)
- A Isselhard
- Institute of Health Economics and Clinical Epidemiology, University Hospital of Cologne, Cologne, Germany.
| | - M Töpper
- Institute of Health Economics and Clinical Epidemiology, University Hospital of Cologne, Cologne, Germany
| | - B Berger-Höger
- Institute for Health and Nursing Science, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - A Steckelberg
- Institute for Health and Nursing Science, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - H Fischer
- Department of Psychosomatics and Psychotherapy, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - F Vitinius
- Department of Psychosomatics and Psychotherapy, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - K Beifus
- Center for Health Economics and Health Services Research, Schumpeter School of Business and Economics, University of Wuppertal, Wuppertal, Germany
| | - J Köberlein-Neu
- Center for Health Economics and Health Services Research, Schumpeter School of Business and Economics, University of Wuppertal, Wuppertal, Germany
| | - R Wiedemann
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - K Rhiem
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - R Schmutzler
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - S Stock
- Institute of Health Economics and Clinical Epidemiology, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
9
|
Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol 2019; 29:2341-2347. [PMID: 30335131 DOI: 10.1093/annonc/mdy460] [Citation(s) in RCA: 155] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). Patients and methods Patients were randomized to paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb). The secondary study end points disease-free survival (DFS) and overall survival (OS) were analyzed. Median follow-up was 47.3 months. HRD was among the exploratory analyses in GeparSixto and was successfully measured in formalin-fixed, paraffin-embedded tumor samples of 193/315 (61.3%) participants with TNBC. Homologous recombination (HR) deficiency was defined as HRD score ≥42 and/or presence of tumor BRCA mutations (tmBRCA). Results A significantly better DFS (hazard ratio 0.56, 95% CI 0.34-0.93; P = 0.022) was observed in patients with TNBC when treated with PMCb. The improvement of OS with PMCb was not statistically significant. Additional carboplatin did not improve DFS or OS in patients with HER2-positive tumors. HR deficiency was detected in 136 (70.5%) of 193 triple-negative tumors, of which 82 (60.3%) showed high HRD score without tmBRCA. HR deficiency independently predicted pCR (ypT0 ypN0) [odds ratio (OR) 2.60, 95% CI 1.26-5.37, P = 0.008]. Adding carboplatin to PM significantly increased the pCR rate from 33.9% to 63.5% in HR deficient tumors (P = 0.001), but only marginally in HR nondeficient tumors (from 20.0% to 29.6%, P = 0.540; test for interaction P = 0.327). pCR rates with carboplatin were also higher (63.2%) than without carboplatin (31.7%; OR 3.69, 1.46-9.37, P = 0.005) in patients with high HRD score but no tmBRCA. DFS rates were improved with addition of carboplatin, both in HR nondeficient (hazard ratio 0.44, 0.17-1.17, P = 0.086) and HR deficient tumors (hazard ratio 0.49, 0.23-1.04, P = 0.059). Conclusions The addition of carboplatin to neoadjuvant PM improved DFS significantly in TNBC. Long-term survival analyses support the neoadjuvant use of carboplatin in TNBC. HR deficiency in TNBC and HRD score in non-tmBRCA TNBC are predictors of response. HRD does not predict for carboplatin benefit.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg, Germany.
| | - K E Weber
- German Breast Group, Neu-Isenburg, Germany
| | - K M Timms
- Myriad Genetics Inc, Salt Lake City, USA
| | - E P Elkin
- The Permanente Medical Group Inc, Oakland, USA
| | - E Hahnen
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany
| | - B Lederer
- German Breast Group, Neu-Isenburg, Germany
| | - C Denkert
- Institute of Pathology, Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - S Braun
- Brustzentrum, Sana Kliniken Offenbach, Offenbach, Germany
| | - C T Salat
- Hämatoonkologische Schwerpunktpraxis, Munich, Germany
| | - M Rezai
- Luisenkrankenhaus, Düsseldorf, Germany
| | - J U Blohmer
- Klinik für Gynäkologie mit Brustzentrum Charité, Berlin, Germany
| | - D M Zahm
- Brustzentrum SRH Waldklinikum, Gera, Germany
| | - C Jackisch
- Brustzentrum, Sana Kliniken Offenbach, Offenbach, Germany
| | - B Gerber
- Frauenklinik, Universität Rostock, Rostock, Germany
| | - P Klare
- Praxisklinik, Berlin, Germany
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany
| | - C Schem
- Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany
| | - S Paepke
- Klinikum rechts der Isar der Technischen Universität München, Frauenklinik, München, Germany
| | - R Schmutzler
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - K Rhiem
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - S Penn
- Myriad Genetics Inc, Salt Lake City, USA
| | - J Reid
- Myriad Genetics Inc, Salt Lake City, USA
| | | | | | | | - M Untch
- Helios-Klinikum Berlin-Buch, Berlin, Germany
| |
Collapse
|
10
|
Herold N, Wappenschmidt B, Markiefka-Schömig B, Driesen J, Keupp K, Kröber S, Hahnen E, Carrizo K, Lampe B, Schmutzler R, Rhiem K. SMARCA4- Risikogen für das kleinzellige Ovarialkarzinome des hyperkalzämischen Typs (SCCOHT). Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- N Herold
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - B Wappenschmidt
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | | | - J Driesen
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - K Keupp
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - S Kröber
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - E Hahnen
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - K Carrizo
- Kaiserswerther Diakonie/Florence Nightingale Krankenhaus, Düsseldorf, Deutschland
| | - B Lampe
- Kaiserswerther Diakonie/Florence Nightingale Krankenhaus, Düsseldorf, Deutschland
| | - R Schmutzler
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - K Rhiem
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| |
Collapse
|
11
|
Herold N, Lichtenheldt F, Richters L, Wappenschmidt B, Hahnen E, Rhiem K, Schmutzler R. Erkrankungsrisiken und Lebensqualität nach prophylaktischer Mastektomie bei BRCA1/2 Mutationsträgerinnen. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- N Herold
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - F Lichtenheldt
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - L Richters
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - B Wappenschmidt
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - E Hahnen
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - K Rhiem
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - R Schmutzler
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| |
Collapse
|
12
|
Neusser S, Willsch K, Biermann J, Wasem J, Rhiem K, Schmutzler R, Neumann A. Die budgetären Auswirkungen der genetischen Risikoklassifikation am Beispiel des hereditären Mammakarzinoms. Das Gesundheitswesen 2018. [DOI: 10.1055/s-0038-1667622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- S Neusser
- Universität Duisburg Essen, Lehrstuhl für Medizinmanagement, Essen, Deutschland
| | - K Willsch
- Universität Duisburg Essen, Lehrstuhl für Medizinmanagement, Essen, Deutschland
| | - J Biermann
- Universität Duisburg Essen, Lehrstuhl für Medizinmanagement, Essen, Deutschland
| | - J Wasem
- Universität Duisburg Essen, Lehrstuhl für Medizinmanagement, Essen, Deutschland
| | - K Rhiem
- Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Deutschland
| | - R Schmutzler
- Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Deutschland
| | - A Neumann
- Universität Duisburg Essen, Lehrstuhl für Medizinmanagement, Essen, Deutschland
| |
Collapse
|
13
|
Beck E, Schmutzler R, Duckert F. Inhibition of Fibrinolysis and Fibrinogenolysis in Man: Comparison of ε-Aminocaproic Acid and Kallikrein Inhibitor. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1660337] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryInhibitor of kallikrein and trypsin (KI) extracted from bovine parotis was compared with ε-aminocaproic acid (EACA): both substances inhibit fibrinolysis induced with streptokinase. EACA is a strong inhibitor of fibrinolysis in concentrations higher than 0, 1 mg per ml plasma. The same amount and higher concentrations are not able to inhibit completely the proteolytic-side reactions of fibrinolysis (fibrinogenolysis, diminution of factor V, rise of fibrin-polymerization-inhibitors). KI inhibits well proteolysis of plasma components in concentrations higher than 2,5 units per ml plasma. Much higher amounts of KI are needed to inhibit fibrinolysis as demonstrated by our in vivo and in vitro tests.Combination of the two substances for clinical use is suggested. Therapeutic possibilities are discussed.
Collapse
|
14
|
Abstract
ZusammenfassungEs wird über die Kombination eines Faktor-VIII- und Faktor-XI-Mangels bei einem Patienten mit schwerer Blutungsneigung berichtet. Die Schwierigkeiten der Differentialdiagnose werden aufgezeigt und ähnliche Fälle in der Literatur diskutiert.
Collapse
|
15
|
Abstract
ZusammenfassungDie einzelnen Etappen einer 20jährigen Geschichte der klinischen Behandlung des akuten Herzinfarktes mit Streptokinase werden gedanklich noch einmal durchlaufen. Da der Koronarverschluß in 80-90 % ein Thrombus ist, bietet sein frisches Substrat die Voraussetzung zur thrombolytischen Behandlung. Tierexperimente, klinische Untersuchungen und multizentrische Studien kontrollierter Patientenkollektive lassen schon in den sechziger Jahren erkennen, daß vor allem 3-4 Std. alte Infarkte den größten Nutzen aus einer damals ausschließlich intravenosen SK-Behandlung ziehen. Seit 1978 kann die koronare Thrombolyse angiographisch bewiesen und die günstigen Auswirkungen der rechtzeitigen Reperfusion auf das Myokard mit modernen Meßmethoden beurteilt werden. Ein Großteil der friiheren Resultate bestatigt sich heute. Die intrakoronare Kurzzeitapplikation von SK mit einem vorausgehenden intravenosen SK-Bolus erreicht in kardiologischen Zentren mit 90% die optimale Lyserate. Die fur das Gros der Infarktpatienten verbleibende systemische hochdosierte Kurzzeitlyse gelingt bisher bei 63%. Diese Rate kann moglicherweise noch verbessert werden.
Collapse
|
16
|
Neusser S, Biermann J, Wasem J, Schmutzler R, Rhiem K, Neumann A. Die budgetären Auswirkungen der genetischen Testung auf BRCA1/2-Mutationen für die Gesetzliche Krankenversicherung. Das Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1605721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- S Neusser
- Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen
| | - J Biermann
- Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen
| | - J Wasem
- Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen
| | - R Schmutzler
- Uniklinik Köln, Zentrum Familiärer Brust- und Eierstockkrebs, Köln
| | - K Rhiem
- Uniklinik Köln, Zentrum Familiärer Brust- und Eierstockkrebs, Köln
| | - A Neumann
- Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen
| |
Collapse
|
17
|
Zeder-Göß C, de Gregorio N, Schnelzer A, Krockenberger M, Schmutzler R, Harter P. Prävalenz von Keimbahnmutationen in BRCA1/2 und anderen Risikogenen bei Patientinnen mit Ovarialkarzinom (AGO TR-1). Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1602363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- C Zeder-Göß
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität München
| | | | | | | | - R Schmutzler
- Universitätsklinikum Köln, Zentrum für Brust- und Eierstockkrebs
| | - P Harter
- Kliniken Essen-Mitte (KEM), Klinik für Gynäkologie und Gynäkologische Onkologie
| |
Collapse
|
18
|
Scherer A, Fischer C, Wassermann K, Rhiem K, Schmutzler R. Langzeit-Follow Up zur psychosozialen Situation von Frauen mit familiärem Brust- und Eierstockkrebs-Risiko nach genetischer Beratung. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1598131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Affiliation(s)
- A Scherer
- Zentrum familiärer Brust- und Eierstockkrebs, Köln
| | - C Fischer
- Zentrum familiärer Brust- und Eierstockkrebs, Köln
| | - K Wassermann
- Zentrum familiärer Brust- und Eierstockkrebs, Köln
| | - K Rhiem
- Zentrum familiärer Brust- und Eierstockkrebs, Köln
| | - R Schmutzler
- Zentrum familiärer Brust- und Eierstockkrebs, Köln
| |
Collapse
|
19
|
Pohl E, Richters L, Hauke J, Ernst C, Kröber S, Niederacher D, Arnold N, Ramser J, Groß E, Gehrig A, Schmidt G, Dutrannoy V, Kast K, Hahnen E, Schmutzler R. Abstract P3-09-04: Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-09-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- E Pohl
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - L Richters
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - J Hauke
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - C Ernst
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - S Kröber
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - D Niederacher
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - N Arnold
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - J Ramser
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - E Groß
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - A Gehrig
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - G Schmidt
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - V Dutrannoy
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - K Kast
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - E Hahnen
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - R Schmutzler
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany; University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Institute of Human Genetics, University Würzburg, Würzburg, Germany; Institute of Human Genetics, Hannover Medical School, Germany; Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin, Berlin, Germany; University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| |
Collapse
|
20
|
Bülow L, Keupp K, Richters L, Pohl E, Wappenschmidt B, Zarghooni V, Reichstein-Gnielinski S, Maringa M, Giesecke J, Rhiem K, Hahnen E, Schmutzler R. Abstract P3-09-03: Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation – The origin of a constitutional mutation in a breast cancer family. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-09-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mosaicisms arise when specific cells within a developing organism mutate to result in two or more cell populations with distinct genotypes. In cases of gonosomal mosaicism a genetic variation is present in both somatic and germline cells.
Here, we describe a large Turkish breast cancer family with four affected individuals. In the Index patient (II-1; age of onset 45 years), a heterozygous deleterious frameshift mutation, c.1310dupA, p.His437Glnfs*2 in BRCA1 was identified using the TruRisk® gene panel designed by the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Predictive genetic testing showed heterozygous carrier status in the daughter (III-1).
The mutation was also analyzed in peripheral blood of the affected mother (I-1; age of onset 45 years) of the index patient by Sanger Sequencing. Interestingly, Sanger sequence did demonstrate the presence of remarkable small peaks presenting the frameshift mutation similar to a mosaic pattern. A second and third independent blood draw within a time frame of four month was tested and a mosaic signal of approximately 10 % was reproducibly detected.
In order to exclude a potential allelic drop out, independent sequencing experiments via next generation sequencing (NGS; TruRisk® gene panel) were performed. Again, the mutation was present with an allele read frequency of 12 %. No other pathogenic mutations were detected in any of the other tested breast cancer susceptibility genes.
To further examine and underscore the presence of gonosomal mosaicism different tissues should be analyzed. As no tumor material or surrounding normal breast tissue was available primary skin fibroblasts were isolated from skin biopsy. Sequencing of cultured primary fibroblasts demonstrated the absence of the familial BRCA1 mutation. With NGS-based CNV analysis as well as MLPA analysis we excluded aberrant copy numbers of BRCA1 in blood and fibroblasts.
In conclusion, our data provide striking evidence for a BRCA1 mosaicism, which is not detectable in all body cells. Due to the inheritance of the BRCA1 mutation to the next generations (II-1 and III-1), we assume the presence of a gonosomal mosaicism in the affected mother (I-1).
Additionally, the history of breast cancer onset in the family indicates that the BRCA1 mosaic mutation carrier do not necessarily have a milder phenotype compared to full heterozygotes. In this context our results implicate the importance of using highly sensitive sequencing platforms in routine diagnostics to ensure the detection of disease causing low-level mosaic mutations.Mosaicisms arise when specific cells within a developing organism mutate to result in two or more cell populations with distinct genotypes. In cases of gonosomal mosaicism a genetic variation is present in both somatic and germline cells.
Here, we describe a large Turkish breast cancer family with four affected individuals. In the Index patient (II-1; age of onset 45 years), a heterozygous deleterious frameshift mutation, c.1310dupA, p.His437Glnfs*2 in BRCA1 was identified using the TruRisk® gene panel designed by the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Predictive genetic testing showed heterozygous carrier status in the daughter (III-1).
The mutation was also analyzed in peripheral blood of the affected mother (I-1; age of onset 45 years) of the index patient by Sanger Sequencing. Interestingly, Sanger sequence did demonstrate the presence of remarkable small peaks presenting the frameshift mutation similar to a mosaic pattern. A second and third independent blood draw within a time frame of four month was tested and a mosaic signal of approximately 10 % was reproducibly detected.
In order to exclude a potential allelic drop out, independent sequencing experiments via next generation sequencing (NGS; TruRisk® gene panel) were performed. Again, the mutation was present with an allele read frequency of 12 %. No other pathogenic mutations were detected in any of the other tested breast cancer susceptibility genes.
To further examine and underscore the presence of gonosomal mosaicism different tissues should be analyzed. As no tumor material or surrounding normal breast tissue was available primary skin fibroblasts were isolated from skin biopsy. Sequencing of cultured primary fibroblasts demonstrated the absence of the familial BRCA1 mutation. With NGS-based CNV analysis as well as MLPA analysis we excluded aberrant copy numbers of BRCA1 in blood and fibroblasts.
In conclusion, our data provide striking evidence for a BRCA1 mosaicism, which is not detectable in all body cells. Due to the inheritance of the BRCA1 mutation to the next generations (II-1 and III-1), we assume the presence of a gonosomal mosaicism in the affected mother (I-1).
Additionally, the history of breast cancer onset in the family indicates that the BRCA1 mosaic mutation carrier do not necessarily have a milder phenotype compared to full heterozygotes. In this context our results implicate the importance of using highly sensitive sequencing platforms in routine diagnostics to ensure the detection of disease causing low-level mosaic mutations.
Citation Format: Bülow L, Keupp K, Richters L, Pohl E, Wappenschmidt B, Zarghooni V, Reichstein-Gnielinski S, Maringa M, Giesecke J, Rhiem K, Hahnen E, Schmutzler R. Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation – The origin of a constitutional mutation in a breast cancer family [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-09-03.
Collapse
Affiliation(s)
- L Bülow
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - K Keupp
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - L Richters
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - E Pohl
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - B Wappenschmidt
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - V Zarghooni
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - S Reichstein-Gnielinski
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - M Maringa
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - J Giesecke
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - K Rhiem
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - E Hahnen
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - R Schmutzler
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| |
Collapse
|
21
|
Keupp K, Richters L, Bülow L, Kröber S, Ernst C, Blümcke B, Versmold B, Waha A, Driesen J, Baasner A, Altmüller J, Thiele H, Nuernberg P, Wappenschmidt B, Neidhardt G, Rhiem K, Schmutzler R, Hahnen E, Hauke J. Abstract P3-08-01: TruRisk® based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: 24% of familial breast cancer (BC) and/or ovarian cancer (OC) cases analyzed within the framework of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) are due to pathogenic BRCA1/2 mutations. However, the mutation prevalence of non-BRCA1/2 genes associated with familial BC and/or BC/OC is largely unknown. Methods: Here, we present the first NGS data generated using the GC-HBOC-designed TruRisk® gene panel. In this study a cohort of 2028 BRCA1/2 and CHEK2 c.1100delC negative index cases was analyzed which comprises consecutive patients from BC families and BC/OC families complying the inclusion criteria of the GC-HBOC. Sequencing was performed on MiSeq, NextSeq, or HiSeq devices (Illumina) using customized SureSelect XT enrichment (Agilent). Data analysis was carried out using the SeqPilot software (version 4.2.2), SophiaDDM (Version 3.5.0.12-p5.0.0) as well as an in house bioinformatics pipeline (Cologne Center for Genomics, varpipe_v2.X). The analysis of copy number variations (CNV) based on NGS-data is currently in process and not yet included in the present mutation prevalence. Results: By focusing on 22 BC/OC associated genes (ATM, BARD1, BRIP1, CDH1, CHEK2, FAM175A, FANCM, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RINT1, STK11, TP53, XRCC2), we identified 71 different deleterious variants in 104 unrelated mutation carriers derived from 2028 BC and BC/OC families (8%). Interestingly, we identified a high prevalence of ATM mutations (n=29, 1.4%) in the familial cases. Additionally mutations in PALB2 (n=27), NBN (n=9), CHEK2 (n=14), BARD1 (n=9), BRIP1 (n=10), RAD51C (n=11) were frequently observed and we confirmed FANCM (n=17) as a novel BC predisposing gene. No mutations in MLH1, MRE11A, PTEN, RAD51D, STK11 and XRCC2 were identified in our collective. Conclusions: Due to the unexpectedly high mutation prevalence in familial cases, our study highlights the importance of these genes to be included in BC/OC routine diagnostics. In contrast we found low occurrence or absence of mutations for a subset of our gene selection which requires further investigation to optimize the gene panel for diagnostic purposes. Nevertheless this approach confirms the TruRisk® gene panel as a reliable tool for this comprehensive analysis.
Citation Format: Keupp K, Richters L, Bülow L, Kröber S, Ernst C, Blümcke B, Versmold B, Waha A, Driesen J, Baasner A, Altmüller J, Thiele H, Nuernberg P, Wappenschmidt B, Neidhardt G, Rhiem K, Schmutzler R, Hahnen E, Hauke J. TruRisk® based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-08-01.
Collapse
Affiliation(s)
- K Keupp
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - L Richters
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - L Bülow
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - S Kröber
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - C Ernst
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - B Blümcke
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - B Versmold
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - A Waha
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - J Driesen
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - A Baasner
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - J Altmüller
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - H Thiele
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - P Nuernberg
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - B Wappenschmidt
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - G Neidhardt
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - K Rhiem
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - R Schmutzler
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - E Hahnen
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - J Hauke
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| |
Collapse
|
22
|
von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman AR, Nekljudova V, Weber KE, Loibl S. Abstract P1-09-02: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Addition of carboplatin to anthracycline/taxane-based neoadjuvant chemotherapy has shown to improve pathological complete response (pCR; ypT0 ypN0) rates in patients with triple-negative breast cancer (TNBC) in two large phase II studies (GeparSixto: von Minckwitz et al, Lancet Oncol 2014, CALGB 40603: Sikov WM, J Clin Oncol 2015). Participants of the GeparSixto study showed an improvement of pCR rate from 36.9 to 53.2% (p=0.005) and DFS by absolute 9% (HR 0.56 95% CI 0.33-0.96] p=0.035) with the addition of carboplatin in the TNBC subgroup. No effect was observed in the HER2-positive subgroup. We here report results on homologous repair deficiency (HRD) status in relation to pCR and DFS in the TNBC subgroup.
Patients and Methods
In the GeparSixto trial (NCT01426880), patients were treated for 18 weeks with paclitaxel 80mg/m2 q1w and non-pegylated-liposomal doxorubicin (NPLD) 20mg/m2 q1w. Patients with TNBC (N=315) received concurrently bevacizumab 15mg/kg i.v. q2w until surgery. All patients were randomized 1:1 to receive concurrently carboplatin AUC 1.5-2 q1w vs no carboplatin. Carboplatin dose was reduced from AUC 2.0 to 1.5 by an amendment after 330 patients. Primary objective is pCR rate (ypT0 ypN0). Event free survival (EFS), and overall survival (OS) were secondary objectives. HR Deficiency status was assessed on FFPE material from pretherapeutic core biopsies. HR Deficiency was defined as either HRD score high or a BRCA mutation.
Results
HRD status was measurable in 193 of 315 TNBC patients. 101 patients of them were randomly assigned to receive carboplatin and 92 to no additional carboplatin. After median follow-up of 34.3 months 43 event free survival (EFS) events have been reported.
HR deficiency was detected in 136 (70.5%) tumors of which 79 (58.1%) showed high HRD score with intact tBRCA. HR deficiency independently predicted pCR (ypT0is ypN0) (odds ratio (OR) 2.506, CI 1.243-5.051, p=0.009). Adding carboplatin to PM significantly increased the pCR rate from 36.6% to 63.2% in HR deficient tumors with intact tBRCA (p=0.018), only marginally from 61.9% to 72.7% in BRCA mutated tumors (p=0.406), and moderately from 20.0% to 40.7% in HR non-deficient tumors (p=0.086). In general, patients with HRD deficient tumors had a better ESF than non HRD deficient ones (HR 1.805 (0.985-3.309); p=0.0526). Patients with high HRD score had an insignificant trend towards an improved EFS compared to those with low HRD score (HR 1.546 (0.764-3.127) p=0.2223). HRD deficiency did not predict carboplatin effect in patients without BRCA mutation (HR 0.8617). In multivariable analysis, only therapy, clinical nodal status before treatment, and lymphocyte predominant breast cancer were significant prognostic on EFS.
Conclusion
Within the GeparSixto study HR deficiency (either HRD score high or BRCA mutation) was associated with a higher pCR in general and an improved EFS. The effect of carboplatin could not be predicted by HR deficiency in this relatively small study. However, the results will help to understand the role of HR deficiency and the value of the HRD score in TNBC especially in patients without BRCA mutation.
Citation Format: von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer J-U, Zahm D-M, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman A-R, Nekljudova V, Weber KE, Loibl S. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-02.
Collapse
Affiliation(s)
- G von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - K Timms
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - M Untch
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - EP Elkin
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - E Hahnen
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - PA Fasching
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - A Schneeweiss
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - CT Salat
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - M Rezai
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - J-U Blohmer
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - D-M Zahm
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - C Jackisch
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - B Gerber
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - P Klare
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Kümmel
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Paepke
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - R Schmutzler
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Chau
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - J Reid
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - A-R Hartman
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - V Nekljudova
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - KE Weber
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| |
Collapse
|
23
|
Van den Bulcke M, Boccia S, de Censi A, Decoster L, Frederici A, Kholmanskikh O, Nowak F, Peeters M, Rolfo C, Schmutzler R, Salgado R, Vermeesch J. Public Health Genomics in Cancer. Eur J Public Health 2016. [DOI: 10.1093/eurpub/ckw173.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Wassermann K, Rhiem K, Schmutzler R. Der Einfluss von Disstress und Persönlichkeitsfaktoren auf die Entscheidung über präventive Maßnahmen nach Feststellung einer BRCA-Mutation. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
25
|
Puppe J, van de Ven M, van der Burg E, Boon U, van Tellingen O, Bouwman P, Mallmann P, Schmutzler R, van Lohuizen M, Jonkers J. EZH2 inhibition sensitizes BRCA1-deficient breast tumors to the PI3K inhibitor BKM120. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
26
|
Rhiem K, Engel C, Hahnen E, Engel J, Niederacher D, Sutter C, Varon-Mateeva R, Steinemann D, Arnold N, Dworniczak B, Wang-Gohrke S, Gehrig A, Meindl A, Schmutzler R. BRCA1/2-Mutationsprävalenz bei Patientinnen mit Triple-negativem Mammakarzinom und ohne familiäre Belastung für Brust- und Eierstockkrebs. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
27
|
Puppe J, Opdam M, Jozwiak K, Schouten PC, Rodenhuis S, Hauptmann M, Hahnen E, Mallmann P, Schmutzler R, Linn S, Jonkers J. EZH2 is overexpressed in breast tumors with a BRCA1-like DNA copy number profile. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
28
|
Rhiem K, Markiefka B, Giesecke J, Hahnen E, Büttner R, Schmutzler R. Entwicklung eines integrierten Versorgungsmoduls „BRCA-Diagnostik“ zur Feststellung einer Therapierelevanz mit dem PARP-Inhibitor Olaparib beim rezidivierten platin-sensitiven HSOC. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
29
|
Kommoss S, Harter P, Hauke J, Heitz F, Reuss A, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Heubner M, Kast K, Braicu I, Hahnen E, Schmutzler R. Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
30
|
Rhiem K, Richters L, Hahnen E, Lampe B, Rezai M, Göhring UJ, Schumacher C, Kümmel S, Ataseven B, Schmutzler R. Benchmarking der Checkliste zur Erfassung einer erblichen Belastung für Brust- und/oder Eierstockkrebs. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
31
|
Keupp K, Kirfel J, Köhler J, Kröber S, Nürnberg P, Rhiem K, Wappenschmidt B, Schmutzler R. Prädiktive BRCA1/2-Gendiagnostik auf der Basis von Gewebeanalysen. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Herold N, Hauke J, Heimbach A, Richters L, Kröber S, Weber- Lassalle N, Pohl E, Wappenschmidt B, Neidhardt G, Rhiem K, Schmutzler R, Hahnen E. Erste Phänotypdaten für moderate Risikogene des TruRisk® Genpanels. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
33
|
Müller D, Danner M, Stock S, Rhiem K, Schmutzler R, Stollenwerk B. Economic modeling of risk-adapted screen-and-treat strategies in women at high-risk for breast or ovarian cancer. Gesundheitswesen 2015. [DOI: 10.1055/s-0035-1563006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Eccles DM, Mitchell G, Monteiro ANA, Schmutzler R, Couch FJ, Spurdle AB, Gómez-García EB. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol 2015; 26:2057-65. [PMID: 26153499 DOI: 10.1093/annonc/mdv278] [Citation(s) in RCA: 138] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 06/08/2015] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Increasing use of BRCA1/2 testing for tailoring cancer treatment and extension of testing to tumour tissue for somatic mutation is moving BRCA1/2 mutation screening from a primarily prevention arena delivered by specialist genetic services into mainstream oncology practice. A considerable number of gene tests will identify rare variants where clinical significance cannot be inferred from sequence information alone. The proportion of variants of uncertain clinical significance (VUS) is likely to grow with lower thresholds for testing and laboratory providers with less experience of BRCA. Most VUS will not be associated with a high risk of cancer but a misinterpreted VUS has the potential to lead to mismanagement of both the patient and their relatives. DESIGN Members of the Clinical Working Group of ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) global consortium (www.enigmaconsortium.org) observed wide variation in practices in reporting, disclosure and clinical management of patients with a VUS. Examples from current clinical practice are presented and discussed to illustrate potential pitfalls, explore factors contributing to misinterpretation, and propose approaches to improving clarity. RESULTS AND CONCLUSION Clinicians, patients and their relatives would all benefit from an improved level of genetic literacy. Genetic laboratories working with clinical geneticists need to agree on a clinically clear and uniform format for reporting BRCA test results to non-geneticists. An international consortium of experts, collecting and integrating all available lines of evidence and classifying variants according to an internationally recognized system, will facilitate reclassification of variants for clinical use.
Collapse
Affiliation(s)
- D M Eccles
- Faculty of Medicine Academic Unit of Cancer Sciences, Southampton General Hospital, Southampton, UK
| | - G Mitchell
- Familial Cancer Centre, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia Hereditary Cancer Program, Department of Medical Oncology, University of British Columbia, Vancouver, Canada
| | - A N A Monteiro
- Cancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, USA
| | - R Schmutzler
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), University Hospital Cologne, Cologne, Germany
| | - F J Couch
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA
| | - A B Spurdle
- Molecular Cancer Epidemiology Laboratory, Division of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, BNE, Herston, Australia
| | - E B Gómez-García
- Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands
| | | |
Collapse
|
35
|
Puppe J, ter Brugge P, Seressi M, van Tellingen O, van der Burg E, Boon U, Bouwman P, Mallmann P, Schmutzler R, van Lohuizen M, Jonkers J. Combination therapy of the EZH2 inhibitor GSK126 and the PARP inhibitor Olaparib shows in vivo synergy in a patient-derived xenograft model of BRCA1-deficient breast cancer. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
36
|
Dunmur RE, Murray M, Schmutzler R, Gagnaire D. Effect of Ring Asymmetry on Pseudorotation at Five-Coordinate Phosphorus in Phosphadiazetidinones. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/znb-1970-0902] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Non-equivalence of fluorine atoms has been observed in the 19F n.m.r. spectra of 1-alkyl-1,1-difluoro-N-methyl-N′-phenyl-1,2,4-phosphadiazetidin-3-ones at -40°C but not in the spectra of analogous N,N′-dimethyl compounds and a mechanism for pseudorotation in these compounds is proposed to explain this difference.
Collapse
Affiliation(s)
- R. E. Dunmur
- Institut für Anorganische Chemie der Technischen Universität Braunschweig
| | - M. Murray
- Institut für Anorganische Chemie der Technischen Universität Braunschweig
| | - R. Schmutzler
- Institut für Anorganische Chemie der Technischen Universität Braunschweig
| | - D. Gagnaire
- Centre d’Etudes Nucleaires de Grenoble, Avenue des Martyrs, Grenoble, France
| |
Collapse
|
37
|
Johannesen RB, Peake SC, Schmutzler R. Notizen: The Fluorine-19 NMR Spectrum of Methylthiotetrafluorophosphorane. Zeitschrift für Naturforschung B 2014. [DOI: 10.1515/znb-1974-9-1031] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The low-temperature 19F NMR spectrum of the stereochemically non-rigid compound, CH3SPF4, shows three fluorine environments, one for the equatorial and two for the nonequivalent axial fluorine atoms. Each of the twelve lines of the upfield 19F- (axial) resonance shows further fine structure, due to coupling between 19F and the protons of the CH3S group. The center peaks of the two multiplet components reveal apparent quintet structure which, based on a computer simulation of the 19F spectrum of CH3SPF4, is rationalized in terms of accidental overlap of two quartets.
Collapse
Affiliation(s)
- Rolf B. Johannesen
- U.S. Department of Commerce, National Bureau of Standards, Washington, D.C. 20234, U.S.A
| | - S. C. Peake
- Inorganic Chemistry Laboratory, South Parks Road, Oxford OX1 3QR, England
| | - R. Schmutzler
- Lehrstuhl B für Anorganische Chemie der Technischen Universität Braunschweig
| |
Collapse
|
38
|
Blazer TA, Schmutzler R, Gregor IK. Mass Spectroscopic Studies of Phosphorus-Fluorine Compounds. Compounds containing Five-coordinate Phosphorus. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/znb-1969-0903] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The mass spectra of a number of phosphorus-fluorine compounds containing five-covalent phosphorus have been obtained. The major fragment ions for each compound are tabulated together with some probable ion assignments.
Collapse
Affiliation(s)
- T. A. Blazer
- E. I. du Pont de Nemours & Co., Inc., Explosives Department, Repauno Development Laboratory, Gibbstown, N.J., U.S.A., (T.A.B.) and Experimental Station Laboratory, Wilmington, Delaware, U.S.A. (R.S.)
| | - R. Schmutzler
- E. I. du Pont de Nemours & Co., Inc., Explosives Department, Repauno Development Laboratory, Gibbstown, N.J., U.S.A., (T.A.B.) and Experimental Station Laboratory, Wilmington, Delaware, U.S.A. (R.S.)
| | - I. K. Gregor
- School of Chemistry, The University of New South Wales, Box 1, Post Office, Kensington, 2033 Australia
| |
Collapse
|
39
|
Shevchenko IV, Furmanova MV, Kukhar VP, Schmutzler R. cis-trans-Isomerie in 1,5-Diaza-2,4-Diphosphorinan-6-onen cis-trans-Isomerism in 1,5-Diaza-2,4-diphosphorinan-6-ones. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/znb-1992-0218] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The methylene-bis(dialkylaminochlorophosphines) 2a and 2b react with N,N′-dimethyl- N,N′-bis(trimethylsilyl)urea 1 to give the 1,5-diaza-2,4-diphosphorinan-6-ones, 4a and 4b, each of which exists as two isomers. Sulfuration of 4a and 4b led to the stable derivatives, 5a and 5b, which, with the help of column chromatography, were separated into pure cis- and trans-isomers. The structures were established, based upon NMR-spectroscopic, chemical and analytical data.
Collapse
Affiliation(s)
- I. V. Shevchenko
- Institut für Bioorganische Chemie der Ukrainischen Akademie der Wissenschaften, ul. Murmanskaya 5, 252660 Kiev, UdSSR
| | - M. V. Furmanova
- Institut für Bioorganische Chemie der Ukrainischen Akademie der Wissenschaften, ul. Murmanskaya 5, 252660 Kiev, UdSSR
| | - V. P. Kukhar
- Institut für Bioorganische Chemie der Ukrainischen Akademie der Wissenschaften, ul. Murmanskaya 5, 252660 Kiev, UdSSR
| | - R. Schmutzler
- Institut für Anorganische und Analytische Chemie der Technischen Universität, Hagenring 30, D-W-3300 Braunschweig
| |
Collapse
|
40
|
Affiliation(s)
- J. F. Nixon
- Chemical Laboratory, University of Sussex, Brighton BNI 9QJ, Sussex, England
| | - M. Murray
- Institut für Anorganische Chemie der Technischen Universität, 33 Braunschweig, Germany
| | - R. Schmutzler
- Institut für Anorganische Chemie der Technischen Universität, 33 Braunschweig, Germany
| |
Collapse
|
41
|
Abstract
The preparation of a series of methyl-substituted piperidyl-fluorophosphoranes is described, of general formula RR′NPF4-nPhn (where RR′N = 2-Me-piperidyl-, 3-Me-piperidyl-, or 4-Me-piperi-dyl; n = 0, 1, or 2), from the cleavage of silicon-nitrogen bonds in methyl-substituted piperidyl silanes by fluorophosphoranes. The structures of the new compounds are deduced from 19F and 31P n.m.r. data.
Collapse
Affiliation(s)
- M. J. C. Hewson
- Lehrstuhl B für Anorganische Chemie der Technischen Universität Braunschweig
| | - R. Schmutzler
- Lehrstuhl B für Anorganische Chemie der Technischen Universität Braunschweig
| |
Collapse
|
42
|
Affiliation(s)
- J. Grosse
- Lehrstuhl B für Anorganische Chemie der Technischen Universität Braunschweig
| | - R. Schmutzler
- Lehrstuhl B für Anorganische Chemie der Technischen Universität Braunschweig
| |
Collapse
|
43
|
Abstract
H1 und P31 (sowie F19, soweit zutreffend) N.M.R.-Daten werden mitgeteilt für einige Verbindungen, die tertiäre Butylgruppen an Phosphor gebunden enthalten. Es wird gezeigt, daß die Verbindung (CH3)3C · P (:O) (F) [N(CH3)2] als ein Gemisch zweier Isomerer vorliegt.
Collapse
Affiliation(s)
- R. Schmutzler
- University Chemical Laboratory, Cambridge, England, and E. I. duPont de Nemours and Co., Inc., Explosives Department, Eastern Laboratory, Gibbstown, New Jersey, U.S.A
| | - G. S. Reddy
- University Chemical Laboratory, Cambridge, England, and E. I. duPont de Nemours and Co., Inc., Explosives Department, Eastern Laboratory, Gibbstown, New Jersey, U.S.A
| |
Collapse
|
44
|
Bartsch R, Freytag M, Goller S, Jones RG, Schmutzler R. Improved Synthetic Route to Unsymmetrically Substituted Phosphinimino-phosphonium Salts. Crystal Structure of Tri-n-butyl- [tris(diethylamino)phosphinimino]phosphonium Chloride. Zeitschrift für Naturforschung B 2014. [DOI: 10.1515/znb-2001-1211] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
The title compound was prepared from tri-n-butyl-chlorophosphonium chloride and N-tri-methylsilyl-tris(diethylamino)-phosphinimine. A low temperature X-ray crystal structure determination revealed PN bond lengths of 156.1(2) and 158.0(2) pm, with a PNP angle of 149.36(17)°.
Collapse
Affiliation(s)
- R. Bartsch
- Institut für Anorganische und Analytische Chemie der Technischen Universität, Postfach 3329, D-38023 Braunschweig, Germany
| | - M. Freytag
- Institut für Anorganische und Analytische Chemie der Technischen Universität, Postfach 3329, D-38023 Braunschweig, Germany
| | - S. Goller
- Institut für Anorganische und Analytische Chemie der Technischen Universität, Postfach 3329, D-38023 Braunschweig, Germany
| | - R G. Jones
- Institut für Anorganische und Analytische Chemie der Technischen Universität, Postfach 3329, D-38023 Braunschweig, Germany
| | - R. Schmutzler
- Institut für Anorganische und Analytische Chemie der Technischen Universität, Postfach 3329, D-38023 Braunschweig, Germany
| |
Collapse
|
45
|
Harris RK, Woplin JR, Schmutzler R. Nuclear Magnetic Resonance Spectra of the [AXn]3Spin System. Part II.19F NMR Spectra offac-Trisubstituted Fluorophosphine Molybdenum Complexes. ACTA ACUST UNITED AC 2014. [DOI: 10.1002/bbpc.19710750211] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
46
|
French J, Ghoussaini M, Edwards S, Meyer K, Michailidou K, Ahmed S, Khan S, Maranian M, O’Reilly M, Hillman K, Betts J, Carroll T, Bailey P, Dicks E, Beesley J, Tyrer J, Maia AT, Beck A, Knoblauch N, Chen C, Kraft P, Barnes D, González-Neira A, Alonso M, Herrero D, Tessier D, Vincent D, Bacot F, Luccarini C, Baynes C, Conroy D, Dennis J, Bolla M, Wang Q, Hopper J, Southey M, Schmidt M, Broeks A, Verhoef S, Cornelissen S, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching P, Loehberg C, Ekici A, Beckmann M, Peto J, dos Santos Silva I, Johnson N, Aitken Z, Sawyer E, Tomlinson I, Kerin M, Miller N, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Bojesen S, Nordestgaard B, Nielsen S, Flyger H, Milne R, Zamora M, Arias Perez J, Benitez J, Anton-Culver H, Brenner H, Müller H, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler R, Engel C, Brauch H, Hamann U, Justenhoven C, Aaltonen K, Heikkilä P, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Sueta A, Bogdanova N, Antonenkova N, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen J, Wu A, Tseng CC, Van Den Berg D, Stram D, Lambrechts D, Peeters S, Smeets A, Floris G, Chang-Claude J, Rudolph A, Nickels S, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Sardella D, Couch F, Wang X, Pankratz V, Lee A, Giles G, Severi G, Baglietto L, Haiman C, Henderson B, Schumacher F, Le Marchand L, Simard J, Goldberg M, Labrèche F, Dumont M, Teo S, Yip C, Ng CH, Vithana E, Kristensen V, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight J, Glendon G, Mulligan A, Devilee P, Seynaeve C, García-Closas M, Figueroa J, Chanock S, Lissowska J, Czene K, Klevebring D, Schoof N, Hooning M, Martens J, Collée J, Tilanus-Linthorst M, Hall P, Li J, Liu J, Humphreys K, Shu XO, Lu W, Gao YT, Cai H, Cox A, Balasubramanian S, Blot W, Signorello L, Cai Q, Pharoah P, Healey C, Shah M, Pooley K, Kang D, Yoo KY, Noh DY, Hartman M, Miao H, Sng JH, Sim X, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, McKay J, Toland A, Ambrosone C, Yannoukakos D, Godwin A, Shen CY, Hsiung CN, Wu PE, Chen ST, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Ponder B, Nevanlinna H, Brown M, Chenevix-Trench G, Easton D, Dunning A. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet 2013; 92:489-503. [PMID: 23540573 PMCID: PMC3617380 DOI: 10.1016/j.ajhg.2013.01.002] [Citation(s) in RCA: 154] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Revised: 12/21/2012] [Accepted: 01/03/2013] [Indexed: 10/27/2022] Open
Abstract
Analysis of 4,405 variants in 89,050 European subjects from 41 case-control studies identified three independent association signals for estrogen-receptor-positive tumors at 11q13. The strongest signal maps to a transcriptional enhancer element in which the G allele of the best candidate causative variant rs554219 increases risk of breast cancer, reduces both binding of ELK4 transcription factor and luciferase activity in reporter assays, and may be associated with low cyclin D1 protein levels in tumors. Another candidate variant, rs78540526, lies in the same enhancer element. Risk association signal 2, rs75915166, creates a GATA3 binding site within a silencer element. Chromatin conformation studies demonstrate that these enhancer and silencer elements interact with each other and with their likely target gene, CCND1.
Collapse
MESH Headings
- Binding Sites
- Breast Neoplasms/genetics
- Case-Control Studies
- Cell Line, Tumor
- Chromatin/chemistry
- Chromatin/genetics
- Chromatin Immunoprecipitation
- Chromosomes, Human, Pair 11/genetics
- Cyclin D1/genetics
- Cyclin D1/metabolism
- Electrophoretic Mobility Shift Assay
- Enhancer Elements, Genetic/genetics
- Female
- GATA3 Transcription Factor/antagonists & inhibitors
- GATA3 Transcription Factor/genetics
- GATA3 Transcription Factor/metabolism
- Gene Expression Regulation, Neoplastic
- Humans
- Luciferases/metabolism
- Polymorphism, Single Nucleotide/genetics
- Promoter Regions, Genetic/genetics
- RNA, Messenger/genetics
- RNA, Small Interfering/genetics
- Real-Time Polymerase Chain Reaction
- Reverse Transcriptase Polymerase Chain Reaction
- Silencer Elements, Transcriptional/genetics
- ets-Domain Protein Elk-4/antagonists & inhibitors
- ets-Domain Protein Elk-4/genetics
- ets-Domain Protein Elk-4/metabolism
Collapse
Affiliation(s)
- Juliet D. French
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Maya Ghoussaini
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Stacey L. Edwards
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Kerstin B. Meyer
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK
| | - Kyriaki Michailidou
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Shahana Ahmed
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Sofia Khan
- Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki 00029, Finland
| | - Mel J. Maranian
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Martin O’Reilly
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK
| | - Kristine M. Hillman
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Joshua A. Betts
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Thomas Carroll
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK
| | - Peter J. Bailey
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Ed Dicks
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Jonathan Beesley
- Department of Genetics, Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
| | - Jonathan Tyrer
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Ana-Teresa Maia
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK
| | - Andrew Beck
- Harvard Medical School and Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Nicholas W. Knoblauch
- Harvard Medical School and Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Constance Chen
- Department of Epidemiology, Harvard School of Public Health, Boston, MA 02215, USA
| | - Peter Kraft
- Department of Epidemiology, Harvard School of Public Health, Boston, MA 02215, USA
- Department of Biostatistics, Harvard School of Public Health, Boston, MA 02215, USA
| | - Daniel Barnes
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Anna González-Neira
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - M. Rosario Alonso
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Daniel Herrero
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Daniel C. Tessier
- Centre d’innovation Génome Québec et Université McGill, Montréal, QC H3A 0G1, Canada
| | - Daniel Vincent
- Centre d’innovation Génome Québec et Université McGill, Montréal, QC H3A 0G1, Canada
| | - Francois Bacot
- Centre d’innovation Génome Québec et Université McGill, Montréal, QC H3A 0G1, Canada
| | - Craig Luccarini
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Caroline Baynes
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Don Conroy
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Joe Dennis
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Manjeet K. Bolla
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Qin Wang
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - John L. Hopper
- Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Melissa C. Southey
- Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Marjanka K. Schmidt
- Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands
- Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands
| | - Annegien Broeks
- Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands
| | - Senno Verhoef
- Family Cancer Clinic, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands
| | - Sten Cornelissen
- Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands
| | - Kenneth Muir
- Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
| | | | | | | | - Peter A. Fasching
- Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
- University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Christian R. Loehberg
- University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Arif B. Ekici
- Institute of Human Genetics, Friedrich Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany
| | - Matthias W. Beckmann
- University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Julian Peto
- Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
| | - Isabel dos Santos Silva
- Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
| | - Nichola Johnson
- Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK
| | - Zoe Aitken
- Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
| | - Elinor J. Sawyer
- Division of Cancer Studies, NIHR Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS Foundation Trust in partnership with King’s College London, London SE1 9RT, UK
| | - Ian Tomlinson
- Welcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, Oxford OX3 7BN, UK
| | - Michael J. Kerin
- Surgery, Clinical Science Institute, Galway University Hospital and National University of Ireland, Galway, Ireland
| | - Nicola Miller
- Surgery, Clinical Science Institute, Galway University Hospital and National University of Ireland, Galway, Ireland
| | - Frederik Marme
- Department of Obstetrics and Gynecology, University of Heidelberg, 69115 Heidelberg, Germany
- National Center for Tumor Diseases, University of Heidelberg, 69120 Heidelberg, Germany
| | - Andreas Schneeweiss
- Department of Obstetrics and Gynecology, University of Heidelberg, 69115 Heidelberg, Germany
- National Center for Tumor Diseases, University of Heidelberg, 69120 Heidelberg, Germany
| | - Christof Sohn
- Department of Obstetrics and Gynecology, University of Heidelberg, 69115 Heidelberg, Germany
| | - Barbara Burwinkel
- Department of Obstetrics and Gynecology, University of Heidelberg, 69115 Heidelberg, Germany
- Molecular Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Pascal Guénel
- INSERM (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer Team, 94807 Villejuif, France
- University Paris-Sud, UMRS 1018, 94807 Villejuif, France
| | - Thérèse Truong
- INSERM (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer Team, 94807 Villejuif, France
- University Paris-Sud, UMRS 1018, 94807 Villejuif, France
| | - Pierre Laurent-Puig
- Université Paris Sorbonne Cité, UMR-S775 INSERM, 75270 Paris Cedex 06, France
| | - Florence Menegaux
- INSERM (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer Team, 94807 Villejuif, France
- University Paris-Sud, UMRS 1018, 94807 Villejuif, France
| | - Stig E. Bojesen
- Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, 2730 Herlev, Denmark
- Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, 2730 Herlev, Denmark
| | - Børge G. Nordestgaard
- Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, 2730 Herlev, Denmark
- Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, 2730 Herlev, Denmark
| | - Sune F. Nielsen
- Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, 2730 Herlev, Denmark
- Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, 2730 Herlev, Denmark
| | - Henrik Flyger
- Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, 2730 Herlev, Denmark
| | - Roger L. Milne
- Genetic & Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - M. Pilar Zamora
- Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid 28046, Spain
| | | | - Javier Benitez
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid 28029, Spain
| | - Hoda Anton-Culver
- Department of Epidemiology, University of California, Irvine, Irvine, CA 92697, USA
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Heiko Müller
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Volker Arndt
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | | | - Alfons Meindl
- Division of Gynaecology and Obstetrics, Technische Universität München, 81675 Munich, Germany
| | - Peter Lichtner
- Institute of Human Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Rita K. Schmutzler
- Division of Molecular Gyneco-Oncology, Department of Gynaecology and Obstetrics, University Cologne, 50931 Cologne, Germany
| | - Christoph Engel
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, 04107 Leipzig, Germany
| | - Hiltrud Brauch
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany
- University of Tübingen, 72074 Tübingen, Germany
| | - Ute Hamann
- Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Christina Justenhoven
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany
- University of Tübingen, 72074 Tübingen, Germany
| | - The GENICA Network
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany
- University of Tübingen, 72074 Tübingen, Germany
- Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, 53113 Bonn, Germany
- Institute and Outpatient Clinic of Occupational Medicine, Saarland University Medical Center and Saarland University Faculty of Medicine, 66421 Homburg, Germany
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), 44789 Bochum, Germany
- Institute of Pathology, Medical Faculty of the University of Bonn, 53123 Bonn, Germany
| | - Kirsimari Aaltonen
- Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki 00029, Finland
- Department of Clinical Genetics, University of Helsinki and Helsinki University Central Hospital, Helsinki, 00029, Finland
| | - Päivi Heikkilä
- Department of Pathology, University of Helsinki and Helsinki University Central Hospital, Helsinki, 00029, Finland
| | - Kristiina Aittomäki
- Department of Clinical Genetics, University of Helsinki and Helsinki University Central Hospital, Helsinki, 00029, Finland
| | - Carl Blomqvist
- Department of Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, 00029, Finland
| | - Keitaro Matsuo
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan
| | - Hidemi Ito
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan
| | - Hiroji Iwata
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan
| | - Aiko Sueta
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan
| | - Natalia V. Bogdanova
- Department of Obstetrics and Gynaecology, Hannover Medical School, 30625 Hannover, Germany
- Department of Radiation Oncology, Hannover Medical School, 30625 Hannover, Germany
| | - Natalia N. Antonenkova
- N.N. Alexandrov Research Institute of Oncology and Medical Radiology, 223040 Minsk, Belarus
| | - Thilo Dörk
- Department of Obstetrics and Gynaecology, Hannover Medical School, 30625 Hannover, Germany
| | - Annika Lindblom
- Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Sara Margolin
- Department of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Arto Mannermaa
- Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, 70211 Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, Biocenter Kuopio, Cancer Center of Eastern Finland, University of Eastern Finland, 70211 Kuopio, Finland
| | - Vesa Kataja
- School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, Biocenter Kuopio, Cancer Center of Eastern Finland, University of Eastern Finland, 70211 Kuopio, Finland
- Cancer Center, Kuopio University Hospital, 70211 Kuopio, Finland
| | - Veli-Matti Kosma
- Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, 70211 Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, Biocenter Kuopio, Cancer Center of Eastern Finland, University of Eastern Finland, 70211 Kuopio, Finland
| | - Jaana M. Hartikainen
- Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, 70211 Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, Biocenter Kuopio, Cancer Center of Eastern Finland, University of Eastern Finland, 70211 Kuopio, Finland
| | | | - Anna H. Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Chiu-chen Tseng
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - David Van Den Berg
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Daniel O. Stram
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Diether Lambrechts
- Laboratory for Translational Genetics, Department of Oncology, University of Leuven, 3000 Leuven, Belgium
- Vesalius Research Center (VRC), VIB, 3000 Leuven, Belgium
| | - Stephanie Peeters
- Multidisciplinary Breast Center, University Hospital Leuven and KU Leuven, 3000 Leuven, Belgium
| | - Ann Smeets
- Multidisciplinary Breast Center, University Hospital Leuven and KU Leuven, 3000 Leuven, Belgium
| | - Giuseppe Floris
- Multidisciplinary Breast Center, University Hospital Leuven and KU Leuven, 3000 Leuven, Belgium
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Anja Rudolph
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Stefan Nickels
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Dieter Flesch-Janys
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- Department of Cancer Epidemiology/Clinical Cancer Registry and Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Paolo Radice
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), 20133 Milan, Italy
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, 20139 Milan, Italy
| | - Paolo Peterlongo
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), 20133 Milan, Italy
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, 20139 Milan, Italy
| | - Bernardo Bonanni
- Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, 20141 Milan, Italy
| | - Domenico Sardella
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, 20139 Milan, Italy
| | - Fergus J. Couch
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
| | - Xianshu Wang
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
| | - Vernon S. Pankratz
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
| | - Adam Lee
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
| | - Graham G. Giles
- Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Victoria 3010, Australia
- Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria 3053, Australia
| | - Gianluca Severi
- Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Victoria 3010, Australia
- Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria 3053, Australia
| | - Laura Baglietto
- Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Victoria 3010, Australia
- Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria 3053, Australia
| | - Christopher A. Haiman
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Brian E. Henderson
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Fredrick Schumacher
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Loic Le Marchand
- Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, HI 96813, USA
| | - Jacques Simard
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, QC G1V 4G2, Canada
| | - Mark S. Goldberg
- Department of Medicine, McGill University, Montreal, QC H3A 1A1, Canada
- Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC H3A 1A1, Canada
| | - France Labrèche
- Département de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, QC H3A 3C2, Canada
| | - Martine Dumont
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, QC G1V 4G2, Canada
| | - Soo Hwang Teo
- Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, 47500 Selangor, Malaysia
- Breast Cancer Research Unit, University Malaya Cancer Research Institute, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia
| | - Cheng Har Yip
- Breast Cancer Research Unit, University Malaya Cancer Research Institute, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia
| | - Char-Hong Ng
- Breast Cancer Research Unit, University Malaya Cancer Research Institute, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia
| | | | - Vessela Kristensen
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, 0310 Oslo, Norway
- Faculty of Medicine (Faculty Division Ahus), University of Oslo, 0318 Oslo, Norway
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
| | - Sandra Deming-Halverson
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
| | - Martha Shrubsole
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
| | - Jirong Long
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
| | - Robert Winqvist
- Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Genetics and Biocenter Oulu, University of Oulu, Oulu University Hospital, 90014 Oulu, Finland
| | - Katri Pylkäs
- Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Genetics and Biocenter Oulu, University of Oulu, Oulu University Hospital, 90014 Oulu, Finland
| | - Arja Jukkola-Vuorinen
- Department of Oncology, Oulu University Hospital, University of Oulu, 90014 Oulu, Finland
| | - Mervi Grip
- Department of Surgery, Oulu University Hospital, University of Oulu, 90014 Oulu, Finland
| | - Irene L. Andrulis
- Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada
- Ontario Cancer Genetics Network, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada
| | - Julia A. Knight
- Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
- Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON M5T 3L9, Canada
| | - Gord Glendon
- Ontario Cancer Genetics Network, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada
| | - Anna Marie Mulligan
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
- Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
| | - Peter Devilee
- Department of Human Genetics & Department of Pathology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands
| | - Caroline Seynaeve
- Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3075 EA Rotterdam, the Netherlands
- Department of Medical Oncology, Erasmus University Medical Center, 3075 EA Rotterdam, the Netherlands
| | - Montserrat García-Closas
- Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK
- Division of Genetics and Epidemiology, Institute of Cancer Research and Breakthrough Breast Cancer Research Centre, London SM2 5NG, UK
- Division of Breast Cancer Research, The Institute of Cancer Research, London SW3 6JB, UK
| | - Jonine Figueroa
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892, USA
| | - Stephen J. Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892, USA
| | - Jolanta Lissowska
- Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, 02-781 Warsaw, Poland
| | - Kamila Czene
- Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17 177, Sweden
| | - Daniel Klevebring
- Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17 177, Sweden
| | - Nils Schoof
- Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17 177, Sweden
| | - Maartje J. Hooning
- Department of Medical Oncology, Erasmus University Medical Center, 3075 EA Rotterdam, the Netherlands
| | - John W.M. Martens
- Department of Medical Oncology, Erasmus University Medical Center, 3075 EA Rotterdam, the Netherlands
| | - J. Margriet Collée
- Department of Clinical Genetics, Erasmus University Medical Center, 3008 AE Rotterdam, the Netherlands
| | | | - Per Hall
- Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17 177, Sweden
| | - Jingmei Li
- Human Genetics Division, Genome Institute of Singapore, Singapore 138672, Singapore
| | - Jianjun Liu
- Human Genetics Division, Genome Institute of Singapore, Singapore 138672, Singapore
| | - Keith Humphreys
- Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17 177, Sweden
| | - Xiao-Ou Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
| | - Wei Lu
- Shanghai Center for Disease Control and Prevention, Shanghai 200336, China
| | - Yu-Tang Gao
- Department of Epidemiology, Shanghai Cancer Institute, Shanghai 200032, China
| | - Hui Cai
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
| | - Angela Cox
- CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield S10 2RX, UK
| | - Sabapathy P. Balasubramanian
- CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield S10 2RX, UK
| | - William Blot
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
- International Epidemiology Institute, Rockville, MD 20850, USA
| | - Lisa B. Signorello
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
- International Epidemiology Institute, Rockville, MD 20850, USA
| | - Qiuyin Cai
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
| | - Paul D.P. Pharoah
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Catherine S. Healey
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Mitul Shah
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Karen A. Pooley
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Daehee Kang
- Seoul National University College of Medicine, Seoul 110-799, Korea
| | - Keun-Young Yoo
- Seoul National University College of Medicine, Seoul 110-799, Korea
| | - Dong-Young Noh
- Seoul National University College of Medicine, Seoul 110-799, Korea
| | - Mikael Hartman
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117597, Singapore
| | - Hui Miao
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117597, Singapore
| | - Jen-Hwei Sng
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore
| | - Xueling Sim
- Centre for Molecular Epidemiology, National University of Singapore, Singapore 117597, Singapore
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University, u. Polabska 4, 70-115 Szczecin, Poland
| | - Jan Lubinski
- Department of Genetics and Pathology, Pomeranian Medical University, u. Polabska 4, 70-115 Szczecin, Poland
| | - Katarzyna Jaworska-Bieniek
- Department of Genetics and Pathology, Pomeranian Medical University, u. Polabska 4, 70-115 Szczecin, Poland
- Postgraduate School of Molecular Medicine, Warsaw Medical University, ul. Żwirki i Wigury 61, 02-091 Warsaw, Poland
| | - Katarzyna Durda
- Department of Genetics and Pathology, Pomeranian Medical University, u. Polabska 4, 70-115 Szczecin, Poland
| | | | - Valerie Gaborieau
- International Agency for Research on Cancer, 69372 Lyon Cedex 08, France
| | - James McKay
- International Agency for Research on Cancer, 69372 Lyon Cedex 08, France
| | - Amanda E. Toland
- Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - Christine B. Ambrosone
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Drakoulis Yannoukakos
- Molecular Diagnostics Laboratory, IRRP, National Centre for Scientific Research “Demokritos,” Athens 15310, Greece
| | - Andrew K. Godwin
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
| | - Chen-Yang Shen
- Colleague of Public Health, China Medical University, Taichong 40402, Taiwan, ROC
- Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan, ROC
| | - Chia-Ni Hsiung
- Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan, ROC
| | - Pei-Ei Wu
- Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan, ROC
| | - Shou-Tung Chen
- Department of Surgery, Changhua Christian Hospital, Changhua City, Changhua county 500, Taiwan, ROC
| | - Anthony Swerdlow
- Division of Genetics and Epidemiology, Institute of Cancer Research and Breakthrough Breast Cancer Research Centre, London SM2 5NG, UK
- Division of Breast Cancer Research, The Institute of Cancer Research, London SW3 6JB, UK
| | - Alan Ashworth
- Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK
| | - Nick Orr
- Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK
- Division of Breast Cancer Research, The Institute of Cancer Research, London SW3 6JB, UK
| | - Minouk J. Schoemaker
- Division of Genetics and Epidemiology, Institute of Cancer Research and Breakthrough Breast Cancer Research Centre, London SM2 5NG, UK
| | - Bruce A.J. Ponder
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK
| | - Heli Nevanlinna
- Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki 00029, Finland
| | - Melissa A. Brown
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Georgia Chenevix-Trench
- Department of Genetics, Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
| | - Douglas F. Easton
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| | - Alison M. Dunning
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK
| |
Collapse
|
47
|
Beckmann M, Schmutzler R, Emons G, Ramsauer B, Kreienberg R. DGGG-Kommissionen. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1327834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
48
|
Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Paligo M, Aretini P, Kantala J, Aroer B, von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M, Benítez J, Gilbert M, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HEJ, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AMW, Seynaeve C, van der Luijt RB, Devilee P, Easton DF, Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson OT, Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P, Durocher F, Chenevix-Trench G, Beesley J, Chen X, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J. Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer 2012; 106:2016-24. [PMID: 22669161 PMCID: PMC3388557 DOI: 10.1038/bjc.2012.160] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Revised: 03/18/2012] [Accepted: 03/25/2012] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental factors modify breast cancer risk. Two genes of special interest are prohibitin (PHB) and methylene-tetrahydrofolate reductase (MTHFR), both of which are important either directly or indirectly in maintaining genomic integrity. METHODS To evaluate the potential role of genetic variants within PHB and MTHFR in breast and ovarian cancer risk, 4102 BRCA1 and 2093 BRCA2 mutation carriers, and 6211 BRCA1 and 2902 BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) were genotyped for the PHB 1630 C>T (rs6917) polymorphism and the MTHFR 677 C>T (rs1801133) polymorphism, respectively. RESULTS There was no evidence of association between the PHB 1630 C>T and MTHFR 677 C>T polymorphisms with either disease for BRCA1 or BRCA2 mutation carriers when breast and ovarian cancer associations were evaluated separately. Analysis that evaluated associations for breast and ovarian cancer simultaneously showed some evidence that BRCA1 mutation carriers who had the rare homozygote genotype (TT) of the PHB 1630 C>T polymorphism were at increased risk of both breast and ovarian cancer (HR 1.50, 95%CI 1.10-2.04 and HR 2.16, 95%CI 1.24-3.76, respectively). However, there was no evidence of association under a multiplicative model for the effect of each minor allele. CONCLUSION The PHB 1630TT genotype may modify breast and ovarian cancer risks in BRCA1 mutation carriers. This association need to be evaluated in larger series of BRCA1 mutation carriers.
Collapse
Affiliation(s)
- A Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Fischer C, Engel C, Sutter C, Zachariae S, Schmutzler R, Meindl A, Heidemann S, Grimm T, Goecke TO, Debatin I, Horn D, Wieacker P, Gadzicki D, Becker K, Schäfer D, Stock F, Voigtländer T. BRCA1/2testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families. Clin Genet 2011; 82:478-83. [DOI: 10.1111/j.1399-0004.2011.01788.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Rhiem K, Engel C, Graeser M, Kiechle M, Ditsch N, Mundhenke C, Kreienberg R, Tio J, Golatta M, Hönig A, Gadzicki D, Speiser D, Kast K, Briest S, Meindl A, Schmutzler R. Kontralaterales Mammakarzinom-Risiko bei BRCA1/2-negativen Patientinnen mit familiärer Hochrisikosituation. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|